Statements (64)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
|
| gptkbp:acquisition |
gptkb:App_Tec_Laboratory_Services
gptkb:Wu_Xi_Pharma_Tech |
| gptkbp:ceo |
gptkb:Ge_Li
|
| gptkbp:employees |
over 25,000
|
| gptkbp:focus |
gptkb:supply_chain_management
data analysis project management cardiology drug discovery neurology oncology patient engagement patient recruitment quality control rare diseases autoimmune diseases market access biostatistics data management infectious diseases clinical trial management medical writing regulatory submissions formulation development pharmacovigilance therapeutic areas precision medicine health economics manufacturing services real-world evidence commercialization regulatory affairs outcomes research regulatory services metabolic diseases development services clinical development site management bioanalytical services clinical monitoring companion diagnostics clinical supply management biomarker development investigator recruitment |
| gptkbp:founded |
gptkb:2000
|
| gptkbp:founder |
gptkb:Ge_Li
|
| gptkbp:global_presence |
gptkb:Europe
gptkb:Asia gptkb:North_America |
| gptkbp:headquarters |
gptkb:Shanghai,_China
|
| https://www.w3.org/2000/01/rdf-schema#label |
Wu Xi App Tec
|
| gptkbp:partnerships |
biotechnology companies
pharmaceutical companies |
| gptkbp:revenue |
over $1 billion
|
| gptkbp:services |
pharmaceutical research
clinical trial services medical device testing biologics development |
| gptkbp:stock_exchange |
gptkb:NYSE
|
| gptkbp:stock_symbol |
WX
|
| gptkbp:website |
www.wuxiapptec.com
|
| gptkbp:bfsParent |
gptkb:Zai_Lab
|
| gptkbp:bfsLayer |
5
|